InhibRx
11099 North Torrey Pines Road
Suite 130
La Jolla
California
92037
United States
Website: http://inhibrx.com/
Email: info@inhibrx.com
28 articles about InhibRx
-
bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies
1/7/2019
The small size of sdAbs may enable the generation of more complex CAR T cell products such as those designed to combine additional functions into a single CAR molecule or recognize multiple tumor antigens simultaneously.
-
Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
12/6/2018
-Interim data expected in 1H 2019-
-
Inhibrx Wins CARB-X Award of Up to $6M To Accelerate Development of its Novel Antibody, INBRX-111, to Treat Pseudomonas Infections
10/31/2017
InhibRx announced today a significant collaboration with CARB-X.
-
OncoSec Medical Announces First Technology Access Program Agreement With Inhibrx
3/14/2017
-
Inhibrx Adopts DNASTAR Lasergene Software
3/29/2016
-
Inhibrx And The Alpha-1 Project Collaborate To Develop A Recombinant Alpha-1 Antitrypsin With Improved Properties
9/17/2015
-
Five Prime and Inhibrx Ink $452.5 Million Cancer Deal Focusing on GITR Antibodies
7/17/2015
-
Oxford Finance Closes $20 Million Debt Facility With Inhibrx
4/10/2015